Skip to main content
RLAY
NASDAQ Life Sciences

Relay Therapeutics Q2 Revenue Misses by 60%, Loss Widens on Surging R&D Costs

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$19.044
Mkt Cap
$4.304B
52W Low
$3.025
52W High
$20.79
52W Position info
530% above low
Off High info
8.4% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

RLAY has more than doubled off its 52-week low of $3.025.

Summary

Relay Therapeutics reported a sharp Q2 miss, with revenue of just $350K against an $872.73K consensus—a 60% shortfall—while net loss widened to $83.71M, well above the $74.20M estimate. The miss was driven by a jump in R&D spending tied to the zovegalisib clinical program, plus higher legal costs. This follows the May 2026 positive Phase 2 data and a $316M public offering that boosted cash to $911M, extending the runway into 2029. The company now expects to start a Phase 3 trial in 1L breast cancer in early 2027, with a key enrollment update for the ongoing ReDiscover-2 trial in 2L breast cancer due by year-end 2026. The revenue miss and cost overruns raise questions about burn rate and execution, even with a strong cash position. The upcoming ReDiscover-2 update will be a critical catalyst for the stock.

At the time of this announcement, RLAY was trading at $19.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $3.03 to $20.79. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

RLAY - Latest Insights

RLAY
Nov 04, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $18.09 info
Change: +$0.070 (+0.39%) info
Market Cap: $3.997B info
RLAY
Nov 04, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $18.09 info
Change: +$0.070 (+0.39%) info
Market Cap: $3.997B info
RLAY
Sep 22, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.54
Real-time Price: $18.09 info
Change: -$0.450 (-2%) info
Market Cap: $3.997B info
RLAY
Aug 25, 2026, 7:43 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.88
Real-time Price: $18.09 info
Change: -$1.79 (-9%) info
Market Cap: $3.997B info
RLAY
Aug 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $18.09 info
Change: -$1.21 (-6%) info
Market Cap: $3.997B info